Description

GSK’s HIV Strategy Is Shifting Long-Acting—And It Could Redefine the Market Through the 2030s!

GSK reported robust financial performance for 2025, with sales increasing by 7% to over GBP 32 billion. This growth was primarily driven by a strong performance in Specialty Medicines, which saw a 17% increase, complemented by vaccines. The company also experienced an 11% rise in core operating profit and a 12% increase in EPS. Strong cash flow of GBP 8.9 billion has supported future investments and allowed for a dividend increase. Looking forward, GSK has provided guidance for continued profitable growth in 2026, with sales anticipated to grow by 3-5% and core operating profit and EPS by 7-9%. The company also expects notable growth in its Specialty Medicines segment, projecting low double-digit percentage increases. GSK’s strategic focus on R&D and product development yielded significant achievements, including five FDA approvals and the initiation of seven pivotal trials.